Palaia Gaspare, Pippi Roberto, Rocchetti Federica, Caputo Martina, Macali Federica, Mohsen Ahmed, Del Vecchio Alessandro, Tenore Gianluca, Romeo Umberto
Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome.
J Clin Exp Dent. 2022 Oct 1;14(10):e875-e884. doi: 10.4317/jced.59736. eCollection 2022 Oct.
The identification of non-invasive biomarkers from biological fluids collected by liquid biopsy provides new horizons for individualized therapeutic strategies and improves clinical decision-making in OSCC patients. Circulating microRNAs have emerged as biomarkers that may reflect not only the existence of cancer, but also the dynamic, malignant potential, and drug resistance of tumors. The aim of the systematic review is to evaluate and summarize the results of the published studies regarding the use of microRNAs as biomarkers for OSCC.
A literature search was conducted on PubMed, Scopus, Web of Science, and Cochrane databases till November 2020. A total of 34 studies met the inclusion criteria and were therefore subjected to quality assessment. Each study was subjected to data extraction including; patient characteristics, type of fluid sample (whole blood, plasma, serum, or saliva), molecular analysis method, specific dysregulated microRNA, and microRNA expression pattern.
The analysis showed that 57 microRNAs of liquid biopsy samples of four different fluids (whole blood, serum, plasma, and saliva) were analyzed. The prognostic and therapeutic significance of these microRNAs were suggested by several studies; where 41 microRNAs were upregulated while 16 were downregulated.
Scientific evidence supports the interest in the use of microRNAs in the diagnosis and prognosis in OSCC patients; however, further studies in a larger cohort of patients are mandatory to introduce liquid biopsy in the routine clinical practice for the OSCC management. Biomarkers, liquid biopsy, microRNA, oral squamous cell carcinoma, systematic review.
通过液体活检收集的生物体液中无创生物标志物的鉴定为个体化治疗策略提供了新视野，并改善了口腔鳞状细胞癌（OSCC）患者的临床决策。循环微RNA已成为生物标志物，其不仅可以反映癌症的存在，还能反映肿瘤的动态变化、恶性潜能和耐药性。本系统评价的目的是评估和总结已发表的关于使用微RNA作为OSCC生物标志物的研究结果。
截至2020年11月，在PubMed、Scopus、Web of Science和Cochrane数据库中进行了文献检索。共有34项研究符合纳入标准，因此对其进行了质量评估。每项研究都进行了数据提取，包括患者特征、液体样本类型（全血、血浆、血清或唾液）、分子分析方法、特定失调的微RNA以及微RNA表达模式。
分析表明，对四种不同体液（全血、血清、血浆和唾液）的液体活检样本中的57种微RNA进行了分析。多项研究表明了这些微RNA的预后和治疗意义；其中41种微RNA上调，16种下调。
科学证据支持在OSCC患者的诊断和预后中使用微RNA；然而，必须在更大规模的患者队列中进行进一步研究，以便将液体活检引入OSCC管理的常规临床实践中。生物标志物、液体活检、微RNA、口腔鳞状细胞癌、系统评价。
